View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS
Dana Farber 13-09-259 DCIS Registry
Investigator: Kristie A. Bobolis, M.D.